Original Article
Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
N Engl J Med 2007; 356:2582-2590June 21, 2007
- Abstract
Background
Smoldering (asymptomatic) multiple myeloma is an asymptomatic plasma-cell proliferative disorder associated with a high risk of progression to symptomatic multiple myeloma or amyloidosis. Prognostic factors for the progression and outcome of this disease are unclear.
Methods
We searched a computerized database and reviewed the medical records of all patients at Mayo Clinic who fulfilled the criteria of the International Myeloma Working Group for the diagnosis of smoldering multiple myeloma between 1970 and 1995. Bone marrow aspirate and biopsy specimens were studied, and patients were followed throughout the course of disease.
Results
During the 26-year period, 276 patients fulfilled the criteria for smoldering multiple myeloma. During 2131 cumulative person-years of follow-up, symptomatic multiple myeloma or amyloidosis developed in 163 persons (59%). The overall risk of progression was 10% per year for the first 5 years, approximately 3% per year for the next 5 years, and 1% per year for the last 10 years; the cumulative probability of progression was 73% at 15 years. At diagnosis, significant risk factors for progression included the serum level and type of monoclonal protein, the presence of urinary light chain, the extent and pattern of bone marrow involvement, and the reduction in uninvolved immunoglobulins. The proportion of plasma cells in the bone marrow and the serum monoclonal protein level were combined to create a risk-stratification model with three distinct prognostic groups.
Conclusions
The risk of progression from smoldering multiple myeloma to symptomatic disease is related to the proportion of bone marrow plasma cells and the serum monoclonal protein level at diagnosis.
Media in This Article
Figure 1
Bone Marrow–Biopsy Specimens from Two Patients with Smoldering Multiple Myeloma.Figure 2
Probability of Progression to Active Multiple Myeloma or Primary Amyloidosis in Patients with Smoldering Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance (MGUS).Article Activity
- Article
Smoldering multiple myeloma is an asymptomatic proliferative disorder of plasma cells with a high risk of progression to symptomatic, or active, multiple myeloma. Previous studies have used various definitions of the disease, and this variability has resulted in important differences in the reported clinical course of the disease.1-7 International consensus criteria for smoldering multiple myeloma were adopted recently to rectify this problem.8
We report here on the prognosis and risk factors for progression of smoldering multiple myeloma in a large cohort of patients for whom long-term follow-up data were available and in whom the disease was defined with the use of criteria of the International Myeloma Working Group. These criteria do not include karyotyping, fluorescence in situ hybridization (FISH), or magnetic resonance imaging for detection of bone lesions.8 Instead, the group defined smoldering multiple myeloma as a disorder in which the patient has a serum monoclonal protein level of 3 g per deciliter or more or a proportion of plasma cells in the bone marrow of 10% or more but no end-organ damage. The diagnosis of active multiple myeloma requires the presence of a monoclonal protein in serum or urine, plasma cells in the bone marrow, or plasmacytoma and end-organ damage related to plasma-cell proliferation. End-organ damage was defined as hypercalcemia, renal insufficiency, anemia, bone lesions, or recurrent bacterial infections.8
The study cohort was stratified into three prognostic groups at initial diagnosis: group 1 had a proportion of bone marrow plasma cells of 10% or more and a serum monoclonal protein level of 3 g per deciliter or more; group 2, 10% or more bone marrow plasma cells and a serum monoclonal protein level of less than 3 g per deciliter; and group 3, less than 10% bone marrow plasma cells and a serum monoclonal protein level of 3 g per deciliter or more.
Methods
Study Cohort
After the study was approved by the Mayo Clinic's institutional review board, we searched a computerized database and reviewed the medical records of all patients who had been seen at the Mayo Clinic within 30 days after detection of an IgG or IgA monoclonal protein level of 3 g per deciliter or more or bone marrow containing 10% or more plasma cells. Patients were evaluated from 1970 to 1995, an interval allowing for a minimum potential follow-up of 10 years. Patients with active multiple myeloma or primary amyloidosis were excluded, as were patients who had ever received chemotherapy.
Bone Marrow Examination
We estimated the proportion of plasma cells in bone marrow aspirates and in paraffin-embedded bone marrow biopsy specimens stained with hematoxylin and eosin, with a differential count of 200 to 500 cells. In addition, immunoperoxidase stains were applied to paraffin sections of the bone marrow biopsy specimens according to previously published methods9 with the use of antibodies directed against CD138, an antigen normally expressed on the surface of plasma cells (Dako Cytomation), multiple myeloma oncogene 1 (MUM1, Dako Cytomation), and cyclin D1 (Biocare). Cyclin D1 expression is thought to be a surrogate for the translocation t(11;14)(q14;q32); CD138 is a cytoplasmic and Golgi stain, and MUM1 is a nuclear stain. The bone marrow–aspirate, biopsy, and immunoperoxidase stains were reviewed by one of two hematopathologists.
Plasma-cell estimates by all three methods were combined to provide the proportion of bone marrow plasma cells, categorized as 0 to 4%, 5 to 9%, 10 to 14%, and so on. Cases with discordance between the plasma-cell estimates in bone marrow aspirate and biopsy specimens were reviewed individually, and the final plasma-cell estimate represented an average of the aspirate and biopsy estimates. The pattern of involvement of plasma cells in bone marrow (singly distributed cells, small clusters of cells, cells filling at least one interfatty marrow space, or sheets of cells spanning the interfatty spaces)10 and the overall bone marrow cellularity were recorded in each case. Monoclonal proteins were identified with cellulose acetate or agarose-gel electrophoresis in combination with immunoelectrophoresis or immunofixation.11
Follow-up and Study End Point
Follow-up included a review of the medical records of patients at the Mayo Clinic and of death certificates for patients who had died. Patients were sent letters of inquiry if they had not visited the Mayo Clinic in the preceding year. The primary study end point was progression to active multiple myeloma (anemia, hypercalcemia, renal insufficiency, or bone lesions) or amyloidosis (positive results on Congo red staining and characteristic clinical features), with either one requiring therapy.
Statistical Analysis
Progression was calculated in terms of both the cumulative probability and the cumulative incidence of progression. The cumulative probability was calculated by means of a Kaplan–Meier analysis12 in which data from patients who had died were censored; curves were compared with use of the log-rank test.13 The cumulative incidence curve, which explicitly accounted for death as a competing risk, was computed with the method of Gooley et al.14 Effects of potential risk factors on progression rates were examined in a Cox proportional-hazards model.15
The risk of progression to active multiple myeloma or amyloidosis, as compared with that in the general population, was assessed with standardized incidence ratios,16 whereby observed cases were compared with the number expected by applying age-specific and sex-specific incidence rates for multiple myeloma in the white cohort from the Iowa Surveillance, Epidemiology, and End Results program17 to the person-years of follow-up specific for age, sex, and calendar year in our study cohort. The age-specific and sex-specific incidence rates of amyloidosis were based on data from Olmsted County, Minnesota.18
Results
Characteristics of the Patients
Of the 3549 patients with myeloma diagnosed between 1970 and 1995, 276 (8%) fulfilled the criteria for smoldering multiple myeloma. The median age at diagnosis was 64 years (range, 26 to 90), and only eight patients (3%) were younger than 40 years of age. A total of 171 patients (62%) were men, and 105 (38%) were women.
Laboratory and Bone Marrow Findings
The initial hemoglobin level ranged from 10.0 to 16.8 g per deciliter (median, 13.0). The hemoglobin level was 12 g per deciliter or more in 76% of patients.
The serum monoclonal protein level at the time of diagnosis ranged from 0.5 to 5.4 g per deciliter (median, 2.9). The levels for 11% of the patients were 4 g per deciliter or more (including 1% with 5 g per deciliter or more), those for 37% were 3 to 3.9 g per deciliter, and those for 52% were less than 3 g per deciliter. The monoclonal protein level in the 27 patients in group 3 (with a monoclonal protein spike of ≥3 g per deciliter and <10% plasma cells) ranged from 3.0 to 3.9 g per deciliter (median, 3.1). Of these 27 patients, 26 had monoclonal IgG present in serum, whereas only 2 had a urinary monoclonal protein level of more than 200 mg per 24 hours (240 and 450 mg per 24 hours). Of the 276 patients, 74% had monoclonal IgG, 22.5% had IgA, 0.5% had IgD, and 3% had biclonal immunoglobulins. The light-chain type was κ in 67% and λ in 33%. Concentrations of uninvolved (normal, polyclonal, or background) immunoglobulins were reduced in 83% of 230 patients whose immunoglobulin levels were determined quantitatively. A single reduction in immunoglobulin was found in 31% of patients, whereas 52% had a reduction of both uninvolved immunoglobulins (e.g., reduced IgM and IgA in a patient with a monoclonal IgG).
Immunoelectrophoresis or immunofixation was performed on urine samples from 259 of the patients (94%). Of those patients, 92 (36%) had a monoclonal κ light chain, 43 (17%) had a λ light chain, and 123 (47%) had negative results for monoclonal light chain. A urinary monoclonal protein level of 0.1 g or less per 24 hours was found in 84%; only four patients (1.5%) had a level of more than 1.0 g per 24 hours.
The bone marrow aspirate and biopsy specimens were examined in all 276 patients (Figure 1Figure 1
Bone Marrow–Biopsy Specimens from Two Patients with Smoldering Multiple Myeloma.). In the plasma-cell category, the most common proportion was 15 to 19%. Of the 276 patients, 10% had less than 10% plasma cells in the marrow, and 10% had 50% or more plasma cells. Cyclin D1 was expressed by the plasma cells in 18% of the bone marrow specimens.Outcome
During 2131 cumulative person-years of follow-up (range, 0 to 29; median, 6.1), 85% of the patients with smoldering multiple myeloma died (median follow-up of those still living, 11.6 years). During this period, active multiple myeloma developed in 158 patients (57%), who had a median survival after the time of diagnosis of 3.4 years; amyloidosis developed in 5 (2%) (Table 1Table 1
Relative Risk of Progression among 276 Patients with Smoldering Multiple Myeloma, According to Prognostic Group.). The cumulative probability of progression to active multiple myeloma or amyloidosis was 51% at 5 years, 66% at 10 years, and 73% at 15 years; the median time to progression was 4.8 years (Figure 2Figure 2Probability of Progression to Active Multiple Myeloma or Primary Amyloidosis in Patients with Smoldering Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance (MGUS).). The overall risk of progression was 10% per year for the first 5 years, approximately 3% per year for the next 5 years, and 1% per year for the last 10 years.The number of patients with progression to active multiple myeloma was 522 times the number of persons without smoldering multiple myeloma who would be expected to have active disease, and the risk of amyloidosis was increased by a factor of 50 (Table 1). Of 16 patients with Durie–Salmon stage II disease, 15 had progression to active multiple myeloma; both patients with Durie–Salmon stage III had progression to active multiple myeloma (median time to progression, 13.8 months and 15.1 months). Among patients with progression of smoldering multiple myeloma, 97% had progression to active multiple myeloma. Rates of death owing to other diseases, including cardiovascular and cerebrovascular disease and non–plasma-cell cancers, were 18% at 5 years, 26% at 10 years, 30% at 15 years, and 35% at 20 years. The overall rate of survival was 60% at 5 years, 34% at 10 years, and 20% at 15 years (median, 6.3). In the 128 patients who did not have progression to active disease after more than 10 years after diagnosis, the disease was of the IgG subtype in 81%, the baseline median level of plasma cells in the bone marrow was 16%, the median spike in the serum monoclonal protein level was 2.8 g per deciliter, and uninvolved immunoglobulins were reduced in 78%.
Risk Factors for Progression
We evaluated baseline factors with respect to progression of smoldering multiple myeloma to active disease or amyloidosis in 163 patients. These factors included sex, hemoglobin level, a spike in the serum monoclonal protein level of 4 g per deciliter or more, the type of serum heavy chain, the serum albumin level, the presence and type of urinary light chain, a reduction in levels of uninvolved immunoglobulins, the expression of cyclin D1, the proportion of plasma cells in the bone marrow, involvement of the interfatty marrow space, decreased proportion of normal hematopoietic elements (10% or more below the expected level for age), and assignment to prognostic group 1, 2, or 3 (as defined in the Methods section). Significant baseline risk factors for progression of smoldering multiple myeloma to active disease or amyloidosis in the univariate analysis included the level of serum monoclonal protein (P<0.001), the presence of IgA monoclonal protein (P=0.004), the presence of urinary light chain (P=0.04), the extent of bone marrow involvement (plasma cells, ≥20%; P<0.001), a reduction in levels of uninvolved immunoglobulins (P=0.001), and the pattern of plasma-cell involvement in bone marrow (sheets of cells spanning the interfatty marrow spaces) (P<0.001) (Table 2Table 2
Risk Factors for Disease Progression among 276 Patients with Smoldering Multiple Myeloma (1970–1995).).On the basis of a fitted model containing the proportion of plasma cells in the bone marrow and the serum monoclonal protein level, the risk of progression to active multiple myeloma or amyloidosis at 10 years was 55% for patients with an initial plasma-cell level of 10 to 14%; progression occurred in 70% of the 27 patients who had more than 50% plasma cells in bone marrow (median time to progression, 21 months) (Table 2). The risk of progression to active multiple myeloma or amyloidosis at 10 years was 57% in patients with an initial monoclonal protein level of 2 g per deciliter and 70% in those whose initial level was 5 g per deciliter. Such factors as hemoglobin, sex, serum albumin level, proportion of normal hematopoietic elements, and expression of cyclin D1 were not significantly associated with progression.
On multivariate analysis, the serum monoclonal protein level and the proportion of plasma cells in the bone marrow emerged as significant independent risk factors for progression. On the basis of these findings and the fact that these two variables were also the main components of the definition of smoldering multiple myeloma, we constructed a risk-stratification model containing three risk groups. The cumulative probability of progression at 15 years was 87% for the 106 patients in group 1 (≥10% plasma cells and ≥3 g of monoclonal protein per deciliter), 70% for the 142 patients in group 2 (≥10% plasma cells and <3 g of monoclonal protein per deciliter), and 39% for the 27 patients in group 3 (<10% plasma cells and ≥3 g of monoclonal protein per deciliter) (Figure 3Figure 3
Probability of Progression to Active Multiple Myeloma or Primary Amyloidosis in Patients with Smoldering Multiple Myeloma among Three Risk Groups.). The median time to progression was 2 years in group 1, 8 years in group 2, and 19 years in group 3 (P<0.001). The type of serum heavy chain added significantly to the multivariate model containing the three prognostic risk groups (Table 2).Discussion
The currently accepted definition of smoldering multiple myeloma requires a serum monoclonal protein level of 3 g per deciliter or more, 10% or more plasma cells in the bone marrow, or both in the absence of end-organ damage. It would be interesting to correlate cytogenetic abnormalities with the outcome of smoldering multiple myeloma, but the bone marrow in patients with this disease has few metaphases, and interphase FISH studies are therefore necessary. FISH may identify patients at increased risk, but since our cohort was studied before 1996, FISH was not available. Smoldering multiple myeloma resembles monoclonal gammopathy of undetermined significance (MGUS) in that end-organ damage is absent, but clinically it is far more likely to progress to active multiple myeloma or amyloidosis at 20 years (a 78% probability for smoldering multiple myeloma vs. 21% for MGUS).19
MGUS is characterized by a serum monoclonal protein level of less than 3 g per deciliter, a proportion of plasma cells in the bone marrow that is less than 10%, and an absence of related organ or tissue impairment (i.e., no end-organ damage such as hypercalcemia, renal insufficiency, anemia, or lytic bone lesions related to the plasma-cell disorder). MGUS and smoldering multiple myeloma are asymptomatic and should not be treated. Active multiple myeloma is characterized by a serum monoclonal protein level that is usually more than 3 g per deciliter or a urinary monoclonal protein, usually more than 10% plasma cells in the bone marrow, and most important, end-organ damage caused by plasma-cell proliferation (Figure 4Figure 4
Characteristics of Active Multiple Myeloma and Its Precursors.).Estimates of the frequency of smoldering multiple myeloma have been affected by the variability in the criteria used to establish the diagnosis.3,6 Inconsistent diagnostic criteria in previous studies have resulted in the reporting of variable median times to progression.1-7 Our study shows that the risk of progression is significantly affected by the level of monoclonal protein, the proportion of bone marrow plasma cells, or both. There were also substantial differences in the median time to progression among the three risk groups (2, 8, and 19 years).
Our study shows that the overall risk of progression in smoldering multiple myeloma is greatly influenced by the time elapsed since diagnosis, in contrast to the risk of progression in MGUS,19 which remains constant over time. We found that the overall risk of progression among patients with smoldering multiple myeloma was approximately 10% per year in the first 5 years and 3% per year in the next 5 years with a decrease to 1% per year thereafter. No such time-dependent change in risk occurs with MGUS.19
Other investigators have reported that the IgA isotype and the presence of urinary monoclonal protein are adverse prognostic factors for patients with smoldering multiple myeloma.5,6,20 In contrast to these findings, the presence of urinary monoclonal protein, although significant on univariate analysis in our study, did not achieve statistical significance in the multivariate analysis. The roles of the serum free light-chain ratio and magnetic resonance imaging in determining the outcome of smoldering multiple myeloma are unknown and require investigation.
The age and sex of the patients in our study and the distribution of heavy-chain and light-chain types were similar to those in patients with active multiple myeloma.21 However, other findings, such as a reduction in the level of uninvolved immunoglobulins19,21 and the presence of monoclonal urinary light chains, were intermediate between those in patients with active multiple myeloma and those in patients with MGUS.
On the basis of our experience, we suggest that the standard of care for patients with smoldering multiple myeloma should be close follow-up every few months. Physicians should repeat the pertinent laboratory tests 2 to 3 months after the initial recognition of the disease to rule out an early active form; if the results are stable, the studies should initially be repeated every 4 to 6 months. However, given the high risk of progression among patients in prognostic groups 2 and 3, along with the availability of new active agents for the treatment of active multiple myeloma, investigational approaches may be considered for selected patients in appropriate clinical trials. Ongoing trials are testing the use of bisphosphonates, interleukin-1β inhibitors, clarithromycin, dehydroepiandrosterone, and thalidomide in the treatment of smoldering multiple myeloma in an attempt to delay progression to active multiple myeloma.22,23
Supported in part by grants (CA62242 and CA107476) from the National Cancer Institute.
No potential conflict of interest relevant to this article was reported.
We thank the Mayo Clinic Cancer Center, which provided hematoxylin and eosin staining and immunohistochemical processing of the bone marrow–biopsy specimens; Barbara A. Todd, for obtaining the bone marrow material for evaluation; and the Section of Scientific Publications at Mayo Clinic, for providing assistance with the preparation of the manuscript.
Source Information
From the Division of Hematology (R.A.K., A.D., R.F., S.V.R.), the Department of Laboratory Medicine and Pathology (E.D.R., P.J.K., J.M.H.), the Division of Biostatistics (T.M.T., D.R.L., M.F.P.), the Department of Immunology (D.F.J.), and the Department of Health Sciences Research (L.J.M.), Mayo Clinic, Rochester, MN.
Address reprint requests to Dr. Kyle at the Division of Hematology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, or at kyle.robert@mayo.edu.
- References
References
1
Kyle RA ,Greipp PR . Smoldering multiple myeloma. N Engl J Med 1980;302:1347-1349
Full Text | Web of Science | Medline2
Alexanian R ,Barlogie B ,Dixon D . Prognosis of asymptomatic multiple myeloma. Arch Intern Med 1988;148:1963-1965
CrossRef | Web of Science | Medline3
Dimopoulos MA ,Moulopoulos A ,Smith T ,Delasalle KB ,Alexanian R . Risk of disease progression in asymptomatic multiple myeloma. Am J Med 1993;94:57-61
CrossRef | Web of Science | Medline4
Facon T ,Menard JF ,Michaux JL , et al. Prognostic factors in low tumour mass asymptomatic multiple myeloma: a report on 91 patients. Am J Hematol 1995;48:71-75
Web of Science | Medline5
Weber DM ,Dimopoulos MA ,Moulopoulos LA ,Delasalle KB ,Smith T ,Alexanian R . Prognostic features of asymptomatic multiple myeloma. Br J Haematol 1997;97:810-814
CrossRef | Web of Science | Medline6
Cesana C ,Klersy C ,Barbarano L , et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol 2002;20:1625-1634
CrossRef | Web of Science | Medline7
Rosinol L ,Blade J ,Esteve J , et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol 2003;123:631-636
CrossRef | Web of Science | Medline8
International Myeloma Working Group
CrossRef | Web of Science | Medline9
Kurtin PJ ,Hobday KS ,Ziesmer S ,Caron BL . Demonstration of distinct antigenic profiles of small B-cell lymphomas by paraffin section immunohistochemistry. Am J Clin Pathol 1999;112:319-329
Web of Science | Medline10
Sukpanichnant S ,Cousar JB ,Leelasiri A ,Graber SE ,Greer JP ,Collins RD . Diagnostic criteria and histologic grading in multiple myeloma: histologic and immunohistologic analysis of 176 cases with clinical correlation. Hum Pathol 1994;25:308-318
CrossRef | Web of Science | Medline11
Kyle RA, Katzmann JA, Lust JA, Dispenzieri A. Immunochemical characterization of immunoglobulins. In: Rose NR, Hamilton RG, Detrick B, eds. Manual of clinical laboratory immunology. 6th ed. Washington, DC: ASM Press. 2002:71-91.
12
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science13
Peto R ,Peto J . Asymptotically efficient rank invariant test procedures. J R Stat Soc [A] 1972;135:185-207
CrossRef | Web of Science14
Gooley TA ,Leisenring W ,Crowley J ,Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706
CrossRef | Web of Science | Medline15
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-22016
Berry G . The analysis of mortality by the subject-years method. Biometrics 1983;39:173-184
CrossRef | Web of Science | Medline17
Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat database: incidence — SEER 9 Regs Public Use, Nov 2004 Sub (1973-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission. (Accessed May 25, 2007, at http://www.seer.cancer.gov.)
18
Kyle RA ,Linos A ,Beard CM , et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992;79:1817-1822
Web of Science | Medline19
Kyle RA ,Therneau TM ,Rajkumar SV , et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-569
Full Text | Web of Science | Medline20
Weber DM ,Wang LM ,Delasalle KB ,Smith T ,Alexanian R . Risk factors for early progression of asymptomatic multiple myeloma. Hematol J 2003;4:Suppl 1:S31-S31
CrossRef21
Kyle RA ,Gertz MA ,Witzig TE , et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33
CrossRef | Web of Science | Medline22
Rajkumar SV ,Dispenzieri A ,Fonseca R , et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001;15:1274-1276
CrossRef | Web of Science | Medline23
Rajkumar SV ,Gertz MA ,Lacy MQ , et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003;17:775-779
CrossRef | Web of Science | Medline
- Citing Articles (84)
Citing Articles
1
S. Vincent Rajkumar. (2012) Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. American Journal of Hematology 87:1, 78-88
CrossRef2
Sumit Madan, Philip R. Greipp. 2011. Plasma Cell Disorders. , 287-306.
CrossRef3
Prashant Kapoor, S. Vincent Rajkumar. (2011) Update on risk stratification and treatment of newly diagnosed multiple myeloma. International Journal of Hematology 94:4, 310-320
CrossRef4
R. Parrón Cambero, I. Rivera, A. Santacruz Arévalo. (2011) Amyloidosis of the hip. Presentation of a case and a review of the literature. Revista Española de Cirugía Ortopédica y Traumatología (English Edition) 55:5, 385-388
CrossRef5
R. Parrón Cambero, I. Rivera, A. Santacruz Arévalo. (2011) Amiloidosis de cadera. Presentación de un caso y revisión de la bibliografía. Revista Española de Cirugía Ortopédica y Traumatología 55:5, 385-388
CrossRef6
Esther Tan, Brendan M. Weiss, Esther Mena, Neha Korde, Peter L. Choyke, Ola Landgren. (2011) Current and future imaging modalities for multiple myeloma and its precursor states. Leukemia & Lymphoma 52:9, 1630-1640
CrossRef7
Rajkumar, S. Vincent, Larson, Dirk, Kyle, Robert A., . (2011) Diagnosis of Smoldering Multiple Myeloma. New England Journal of Medicine 365:5, 474-475
Full Text8
Adriele Ferreira Gouvêa, Ana Carolina Prado Ribeiro, Jorge Esquiche León, Román Carlos, Oslei Paes de Almeida, Márcio Ajudarte Lopes. (2011) Head and neck amyloidosis: clinicopathological features and immunohistochemical analysis of 14 cases. Journal of Oral Pathology & Medicineno-no
CrossRef9
Sigurdur Y Kristinsson, Alex R Minter, Neha Korde, Esther Tan, Ola Landgren. (2011) Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. Expert Review of Molecular Diagnostics 11:6, 593-603
CrossRef10
Jennifer M. Bird, Roger G. Owen, Shirley D’Sa, John A. Snowden, Guy Pratt, John Ashcroft, Kwee Yong, Gordon Cook, Sylvia Feyler, Faith Davies, Gareth Morgan, Jamie Cavenagh, Eric Low, Judith Behrens, . (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology 154:1, 32-75
CrossRef11
W. Edward Jordan, Robert Emmons, Daniel Vogl, Gloria J. Morris. (2011) Monoclonal Gammopathy of Undetermined Significance Versus Smoldering Myeloma: Is Active Surveillance Enough?. Seminars in Oncology 38:3, 327-334
CrossRef12
N. Korde, S. Y. Kristinsson, O. Landgren. (2011) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood 117:21, 5573-5581
CrossRef13
Giovanni D'arena, Paolo G. Gobbi, Chiara Broglia, Stefano Sacchi, Giovanni Quarta, Luca Baldini, Emilio Iannitto, Antonietta Falcone, Roberto Guariglia, Giuseppe Pietrantuono, Oreste Villani, Maria Carmen Martorelli, Giovanna Mansueto, Grazia Sanpaolo, Nicola Cascavilla, Pellegrino Musto. (2011) Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leukemia & Lymphoma 52:5, 771-775
CrossRef14
Charles A. Dinarello. (2011) A clinical perspective of IL-1β as the gatekeeper of inflammation. European Journal of Immunology 41:5, 1203-1217
CrossRef15
S. Vincent Rajkumar. (2011) Treatment of multiple myeloma. Nature Reviews Clinical Oncology 8:8, 479-491
CrossRef16
Shaji Kumar, S. Vincent Rajkumar. 2011. Multiple Myeloma: Molecular Biology, Diagnosis and Treatment. , 315-341.
CrossRef17
Benjamin Kasenda, Anja Rückert, Juliane Farthmann, Georgia Schilling, Dominik Schnerch, Heinrich Prömpeler, Ralph Wäsch, Monika Engelhardt. (2011) Management of Multiple Myeloma in Pregnancy: Strategies for a Rare Challenge. Clinical Lymphoma Myeloma and Leukemia 11:2, 190-197
CrossRef18
Matthew J. Butts, Joseph H. Skalski, Christopher M. Wittich. (2011) 85-Year-Old Man With Epistaxis. Mayo Clinic Proceedings 86:4, 344-347
CrossRef19
Ibrahiem Saeed Abdul-Rahman. (2011) Renal Disease in Hematological Malignancies. Hong Kong Journal of Nephrology 13:1, 5-18
CrossRef20
Palumbo, Antonio, Anderson, Kenneth, . (2011) Multiple Myeloma. New England Journal of Medicine 364:11, 1046-1060
Full Text21
Francesca Gay, Antonio Palumbo. (2011) Management of older patients with multiple myeloma. Blood Reviews 25:2, 65-73
CrossRef22
Jacob Laubach, Paul Richardson, Kenneth Anderson. (2011) Multiple Myeloma. Annual Review of Medicine 62:1, 249-264
CrossRef23
Neha Korde, Irina Maric. (2011) Myelomagenesis: Capturing Early Microenvironment Changes. Seminars in Hematology 48:1, 13-21
CrossRef24
Ola Landgren, S. Vincent Rajkumar. (2011) Development of Early Treatment Strategies for High-Risk Myeloma Precursor Disease in the Future. Seminars in Hematology 48:1, 66-72
CrossRef25
S. Vincent Rajkumar. (2011) Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. American Journal of Hematology 86:1, 57-65
CrossRef26
Sergio Siragusa, William Morice, Morie A. Gertz, Robert A. Kyle, Philip R. Greipp, John A. Lust, Thomas E. Witzig, Martha Q. Lacy, Steven R. Zeldenrust, S. Vincent Rajkumar, Stephen J. Russell, Suzanne R. Hayman, Francis Buadi, Shaji K. Kumar, David Dingli, Angela Dispenzieri. (2011) Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. Annals of Hematology 90:1, 101-106
CrossRef27
Ola Landgren. (2011) Multiple Myeloma Precursor Disease: Current Clinical Dilemma and Future Opportunities. Seminars in Hematology 48:1, 1-3
CrossRef28
Yasushi Matsuyama, Takao Nagashima, Kyoko Honne, Yasuyuki Kamata, Masahiro Iwamoto, Hitoaki Okazaki, Kazuya Sato, Keiya Ozawa, Seiji Minota. (2011) Successful Treatment of a Patient with Rheumatoid Arthritis and IgA-Kappa Multiple Myeloma with Tocilizumab. Internal Medicine 50:6, 639-642
CrossRef29
C. A. Dinarello. (2011) Blocking interleukin-1β in acute and chronic autoinflammatory diseases. Journal of Internal Medicine 269:1, 16-28
CrossRef30
O. Landgren. (2010) Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: New Insights into Pathophysiology and Epidemiology. Hematology 2010:1, 295-302
CrossRef31
Steven R. Schuster, Sundararajan Vincent Rajkumar, Angela Dispenzieri, William Morice, Alvaro Moreno Aspitia, Stephen Ansell, Robert Kyle, Joseph Mikhael. (2010) IgM multiple myeloma: Disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia. American Journal of Hematology 85:11, 853-855
CrossRef32
Jesús San-Miguel, Joan Bladé. 2010. Multiple Myeloma. , 577-598.
CrossRef33
S. Vincent Rajkumar, Robert A. Kyle, Francis K. Buadi. (2010) Advances in the Diagnosis, Classification, Risk Stratification, and Management of Monoclonal Gammopathy of Undetermined Significance: Implications for Recategorizing Disease Entities in the Presence of Evolving Scientific Evidence. Mayo Clinic Proceedings 85:10, 945-948
CrossRef34
Kristen Detweiler-Short, Suzanne Hayman, Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri, Shaji Kumar, Steven R. Zeldenrust, Stephen J. Russell, John A. Lust, Robert A. Kyle, Philip R. Greipp, Thomas E. Witzig, S. Vincent Rajkumar. (2010) Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. American Journal of Hematology 85:10, 737-740
CrossRef35
CL Bi, WJ Chng. 2010. Molecular Genetics of Multiple Myeloma. .
CrossRef36
Lucía López-Corral, Ramón García-Sanz, Jesús F. San Miguel. (2010) Aplicaciones del test sérico de cadenas ligeras libres en las gammapatías monoclonales. Medicina Clínica 135:8, 368-374
CrossRef37
Mary Ann Yancey, Adam J. Waxman, Ola Landgren. (2010) A Case Study Progression to Multiple Myeloma. Clinical Journal of Oncology Nursing 14:4, 419-422
CrossRef38
Adam J. Waxman, Michael Kuehl, Arun Balakumaran, Brendan Weiss, Ola Landgren. (2010) Smoldering (Asymptomatic) Multiple Myeloma: Revisiting the Clinical Dilemma and Looking Into the Future. Clinical Lymphoma, Myeloma & Leukemia 10:4, 248-257
CrossRef39
R A Kyle, B G M Durie, S V Rajkumar, O Landgren, J Blade, G Merlini, N Kröger, H Einsele, D H Vesole, M Dimopoulos, J San Miguel, H Avet-Loiseau, R Hajek, W M Chen, K C Anderson, H Ludwig, P Sonneveld, S Pavlovsky, A Palumbo, P G Richardson, B Barlogie, P Greipp, R Vescio, I Turesson, J Westin, M Boccadoro. (2010) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24:6, 1121-1127
CrossRef40
Charles A. Dinarello. (2010) Why not treat human cancer with interleukin-1 blockade?. Cancer and Metastasis Reviews 29:2, 317-329
CrossRef41
Sagar Lonial. (2010) Presentation and risk stratification – improving prognosis for patients with multiple myeloma. Cancer Treatment Reviews 36, S12-S17
CrossRef42
Shaji Kumar. (2010) Multiple myeloma – current issues and controversies. Cancer Treatment Reviews 36, S3-S11
CrossRef43
Liliana Guedez, William G. Stetler-Stevenson. (2010) The prognostic value of TIMP-1 in multiple myeloma. Leukemia Research 34:5, 576-577
CrossRef44
Brendan M Weiss, W Michael Kuehl. (2010) Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma. Expert Review of Hematology 3:2, 165-174
CrossRef45
Béatrice Bouvard, Mathieu Royer, Daniel Chappard, Maurice Audran, Emmanuel Hoppé, Erick Legrand. (2010) Monoclonal gammopathy of undetermined significance, multiple myeloma, and osteoporosis. Joint Bone Spine 77:2, 120-124
CrossRef46
Sundar Jagannath, Robert A. Kyle, Antonio Palumbo, David S. Siegel, Sonia Cunningham, James Berenson. (2010) The Current Status and Future of Multiple Myeloma in the Clinic. Clinical Lymphoma, Myeloma & Leukemia 10:1, 28-43
CrossRef47
Sundar Jagannath, Robert A. Kyle, Antonio Palumbo, David S. Siegel, Sonia Cunningham, James Berenson. (2010) The Current Status and Future of Multiple Myeloma in the Clinic. Clinical Lymphoma, Myeloma & Leukemia 10:1, E1-E16
CrossRef48
Davide Rossi, Marco Fangazio, Lorenzo De Paoli, Alessia Puma, Paola Riccomagno, Valeria Pinto, Paola Zigrossi, Antonio Ramponi, Guido Monga, Gianluca Gaidano. (2010) Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma. CancerNA-NA
CrossRef49
Vesna V. Radović. (2010) Recommendations for Use of Free Light Chain Assay in Monoclonal Gammopathies. Journal of Medical Biochemistry 29:1, 1-8
CrossRef50
A. K. Stewart, P. G. Richardson, J. F. San-Miguel. (2009) How I treat multiple myeloma in younger patients. Blood 114:27, 5436-5443
CrossRef51
Robert A. Kyle, S. Vincent Rajkumar. (2009) Treatment of Multiple Myeloma: A Comprehensive Review. Clinical Cancer Reviews 3:1, 65-75
CrossRef52
Sigurdur Yngvi Kristinsson, Ola Landgren, Vincent S. Rajkumar. (2009) Novel Therapies in Multiple Myeloma for Newly Diagnosed Nontransplant Candidates. The Cancer Journal 15:6, 473-478
CrossRef53
Sumit Madan, Philip R. Greipp. (2009) The incidental monoclonal protein: Current approach to management of monoclonal gammopathy of undetermined significance (MGUS). Blood Reviews 23:6, 257-265
CrossRef54
R. L. Comenzo. (2009) How I treat amyloidosis. Blood 114:15, 3147-3157
CrossRef55
Stanley S Levinson. 2009. Immunoelectrophoresis. .
CrossRef56
Kelechi Okoli, Farzan Irani, William Horvath. (2009) Multiple Myeloma and Systemic Lupus Erythematosus in a Young Woman. JCR: Journal of Clinical Rheumatology 15:6, 292-294
CrossRef57
Harousseau, Jean-Luc, Moreau, Philippe, . (2009) Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine 360:25, 2645-2654
Full Text58
Yiming Zhou, Bijay Nair, John D Shaughnessy Jr, Marie-Astrid Cartron, Jeff Haessler, Elias Anaissie, Frits van Rhee, John Crowley, Bart Barlogie. (2009) Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile. British Journal of Haematology 145:5, 637-641
CrossRef59
B. M. Weiss, J. Abadie, P. Verma, R. S. Howard, W. M. Kuehl. (2009) A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113:22, 5418-5422
CrossRef60
William G Morice, Dong Chen, Paul J Kurtin, Curtis A Hanson, Ellen D McPhail. (2009) Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia. Modern Pathology
CrossRef61
A Palumbo, S V Rajkumar. (2009) Treatment of newly diagnosed myeloma. Leukemia 23:3, 449-456
CrossRef62
Francesca Patriarca, Maria T. Petrucci, Sara. Bringhen, Luca Baldini, Tommaso Caravita, Paolo Corradini, Alessandro Corso, Francesco Di Raimondo, Antonietta Falcone, Felicetto Ferrara, Fortunato Morabito, Pellegrino Musto, Massimo Offidani, Mario Petrini, Rita Rizzi, Gianpietro Semenzato, Patrizia Tosi, Angelo Vacca, Michele Cavo, Mario Boccadoro, Antonio Palumbo. (2009) Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. European Journal of Haematology 82:2, 93-105
CrossRef63
A Dispenzieri, R Kyle, G Merlini, J S Miguel, H Ludwig, R Hajek, A Palumbo, S Jagannath, J Blade, S Lonial, M Dimopoulos, R Comenzo, H Einsele, B Barlogie, K Anderson, M Gertz, J L Harousseau, M Attal, P Tosi, P Sonneveld, M Boccadoro, G Morgan, P Richardson, O Sezer, M V Mateos, M Cavo, D Joshua, I Turesson, W Chen, K Shimizu, R Powles, S V Rajkumar, B G M Durie. (2009) International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23:2, 215-224
CrossRef64
J. A. Lust, M. Q. Lacy, S. R. Zeldenrust, A. Dispenzieri, M. A. Gertz, T. E. Witzig, S. Kumar, S. R. Hayman, S. J. Russell, F. K. Buadi, S. M. Geyer, M. E. Campbell, R. A. Kyle, S. V. Rajkumar, P. R. Greipp, M. P. Kline, Y. Xiong, L. L. Moon-Tasson, K. A. Donovan. (2009) Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1 -Induced Interleukin 6 Production and the Myeloma Proliferative Component. Mayo Clinic Proceedings 84:2, 114-122
CrossRef65
C. A. Dinarello. (2009) Targeting the Pathogenic Role of Interleukin 1 in the Progression of Smoldering/Indolent Myeloma to Active Disease. Mayo Clinic Proceedings 84:2, 105-107
CrossRef66
Maneesh Jain, Joao Ascensao, Geraldine P. Schechter. (2009) Familial myeloma and monoclonal gammopathy: A report of eight African American families. American Journal of Hematology 84:1, 34-38
CrossRef67
Saša A. Živković, David Lacomis, Suzanne Lentzsch. (2009) Paraproteinemic neuropathy. Leukemia & Lymphoma 50:9, 1422-1433
CrossRef68
Takafumi Okura, Ken-ichi Miyoshi, Tomoaki Nagao, Masanori Jotoku, Daijiro Enomoto, Jun Irita, Mie Kurata, Jitsuo Higaki. (2009) Light Chain Deposition Disease Developing 15 Years Following the Diagnosis of Monoclonal Gammopathy of Undetermined Significance. Internal Medicine 48:2, 101-104
CrossRef69
B. Barlogie, F. van Rhee, J. D. Shaughnessy, J. Epstein, S. Yaccoby, M. Pineda-Roman, K. Hollmig, Y. Alsayed, A. Hoering, J. Szymonifka, E. Anaissie, N. Petty, N. S. Kumar, G. Srivastava, B. Jenkins, J. Crowley, J. B. Zeldis. (2008) Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 112:8, 3122-3125
CrossRef70
Pellegrino Musto, Maria Teresa Petrucci, Sara Bringhen, Tommasina Guglielmelli, Tommaso Caravita, Velia Bongarzoni, Alessandro Andriani, Giovanni D'Arena, Enrico Balleari, Giuseppe Pietrantuono, Mario Boccadoro, Antonio Palumbo, . (2008) A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 113:7, 1588-1595
CrossRef71
Pellegrino Musto, Fiorella D’Auria, Giuseppe Pietrantuono, Sara Bringhen, Fortunato Morabito, Francesco Di Raimondo, Samantha Pozzi, Stefano Sacchi, Mario Boccadoro, Antonio Palumbo. (2008) Role of thalidomide in previously untreated patients with multiple myeloma. Expert Review of Anticancer Therapy 8:10, 1569-1580
CrossRef72
Jo Caers, Isabelle Vande broek, Hendrik De Raeve, Lucienne Michaux, Fabienne Trullemans, Rik Schots, Ben Van Camp, Karin Vanderkerken. (2008) Multiple myeloma - an update on diagnosis and treatment. European Journal of Haematology
CrossRef73
Saad P. Shaheen, Sameer S. Talwalkar, L. Jeffrey Medeiros. (2008) Multiple Myeloma and Immunosecretory Disorders. Advances in Anatomic Pathology 15:4, 196-210
CrossRef74
Laurence H. Beck, David J. Salant. (2008) Glomerular and Tubulointerstitial Diseases. Primary Care: Clinics in Office Practice 35:2, 265-296
CrossRef75
Shaji K. Kumar, David Dingli, Martha Q. Lacy, Angela Dispenzieri, Suzanne R. Hayman, Francis K. Buadi, S. Vincent Rajkumar, Mark R. Litzow, Morie A. Gertz. (2008) Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders. British Journal of Haematology 141:2, 205-211
CrossRef76
R. A. Kyle, S. V. Rajkumar. (2008) Multiple myeloma. Blood 111:6, 2962-2972
CrossRef77
K C Anderson, R A Kyle, S V Rajkumar, A K Stewart, D Weber, P Richardson. (2008) Clinically relevant end points and new drug approvals for myeloma. Leukemia 22:2, 231-239
CrossRef78
M. Jinushi, M. Vanneman, N. C. Munshi, Y.-T. Tai, R. H. Prabhala, J. Ritz, D. Neuberg, K. C. Anderson, D. R. Carrasco, G. Dranoff. (2008) MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proceedings of the National Academy of Sciences 105:4, 1285-1290
CrossRef79
A. Dispenzieri, R. A. Kyle, J. A. Katzmann, T. M. Therneau, D. Larson, J. Benson, R. J. Clark, L. J. Melton, M. A. Gertz, S. K. Kumar, R. Fonseca, D. F. Jelinek, S. V. Rajkumar. (2008) Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111:2, 785-789
CrossRef80
J. Blade, L. Rosinol. (2008) SMM: toward better predictors of progression. Blood 111:2, 479-480
CrossRef81
(2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:1, 46-53
CrossRef82
Robert A. Kyle, S. Vincent Rajkumar. (2007) Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. British Journal of Haematology 139:5, 730-743
CrossRef83
(2007) Study identifies risk factors for progression of smoldering multiple myeloma. Nature Clinical Practice Oncology 4:10, 560-561
CrossRef84
(2007) Smoldering Multiple Myeloma. New England Journal of Medicine 357:10, 1048-1050
Full Text
- Letters
